Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

Hologic’s (HOLX) progress in the domestic and international markets, strong pipeline of products and continued solid performance of the Molecular Diagnostics segment bolster our confidence. However, uncertainty related to COVID-19-related test sales and macroeconomic issues persists. The stock carries a Zacks Rank #3 (Hold) currently.Hologic’s Molecular Diagnostics business is registering strong growth, driven by a combination of newer assays like BV, CV/TV and contributions from Amgen and HSV, as well as s ...